Preparation and in vivo evaluation of immediate-release pellet containing celecoxib solid dispersion

다국어 초록 (Multilingual Abstract)

The aim of this study was to make use of small size of immediate-release (IR) pellet and amorphous state of solid dispersion to increase solubility of celecoxib (CLX), a drug in BCS class II. Primary, binary and ternary solid dispersions were developed to choose the final components for solid dispersion. A ternary novel solid dispersion was prepared by incorporation of one aqueous soluble polymer (povidone k17; PVP 17PF), Methacrylate copolymer-based gastric soluble polymer (Eudragit EPO) and one pH modulator (MgO). This combination was effective to increase solubility in pH 1.2 up to 25–30 %. The mechanismof solubility enhancement was proven by DSC, PRXD, and FT-IR.
Accordingly, hydrogen bonding or electrostatic interaction of CLXwithPVP/EudragitEPOwas themain cause to formthe amorphous state of CLX within polymer cluster which increasing solubility of drug. Besides, MgO played an important role to change microenviroment for solid dispersion.
Pellets containing this solid dispersion were prepared by extrusion and spheronization technique. Effect of four kinds of additive (calciumhydrogen phosphate dihydrate,NaHCO3,crospovidone, and sodium dodecyl sulfate) on dissolution of CLX from IR pellet was also determined. Because of highest dissolution rate, formulation using sodium dodecyl sulfate was used for pharmacokinetics study. Solid dispersion-IR pellet formulation presented bioequivalence and lower variability in comparison with reference product.

참고문헌 (Reference)

1 Fouad EA, "The use of spray-drying to enhance celecoxibsolubility" 1-10, 2011

2 Gupta P, "Stability and solubility ofcelecoxib-PVP amorphous dispersions: a molecular perspective" 21 : 1762-1769, 2004

3 Jachowicz R, "Solid dispersion of ketoprofen in pellets" 206 : 13-21, 2000

4 Tan A, "Silicalipidhybrid (SLH) microcapsules: a novel oral delivery systemfor poorly soluble drugs" 134 : 62-70, 2009

5 Morgen M, "Polymeric nanoparticles forincreased oral bioavailability and rapid absorption using celecoxibas a model of a low-solubility, high-permeability drug" 1-14, 2012

6 Liu Y, "Mechanismof dissolution enhancement and bioavailability of poorly watersoluble celecoxib by preparing stable amorphous nanoparticles" 13 : 589-606, 2010

7 Puri V, "Investigation of atypicaldissolution behavior of an encapsulated amorphous soliddispersion" 100 : 2460-2468, 2011

8 Patlolla RR, "Formulation, characterization and pulmonary depositionof nebulized celecoxib encapsulated nanostructured lipid carriers" 144 : 233-241, 2010

9 Ye G, "Developmentand optimization of solid dispersion containing pellets ofitraconazole prepared by high shear pelletization" 337 : 80-87, 2007

10 SinhaVR, "Complexationof celecoxibwith b-cyclodextrin: characterization of the interactionin solution and in solid state" 94 : 676-687, 2005

11 Ghorab DM, "Colontargetedcelecoxib-loaded Eudragit S100-coated poly-e-caprolactonemicroparticles: preparation, characterization and in vivoevaluation in rats" 1-13, 2011